The traditional view of follicle-stimulating hormone (FSH) as a reproductive hormone is
changing. It has been shown that FSH receptors (FSHRs) are expressed in various extra …

Blocking the action of FSH genetically or pharmacologically in mice reduces body fat, lowers
serum cholesterol, and increases bone mass, making an anti-FSH agent a potential …

Context Follicle-stimulating hormone (FSH) concentrations increase during the
perimenopausal transition and remain high after menopause. Loss of bone mineral density …

Purpose: Androgen deprivation therapy is an established therapy for castration sensitive
prostate cancer and recent studies have observed that patients whose testosterone levels …

Objectives To compare the metabolic changes between men with advanced prostate cancer
commenced on a gonadotropin‐releasing hormone (Gn RH) agonist and those treated with …

Purpose We aimed to compare total orchiectomy, subcapsular orchiectomy, and luteinizing
hormone-releasing hormone (LHRH) analogue treatment in patients with hormone-sensitive …

Background Serum insulin-like factor 3 (INSL3) is a Leydig cell biomarker, but little is known
about the circulating concentration of INSL3 during hypothalamus-pituitary-testicular …

Androgen deprivation therapy (ADT) using gonadotropin-releasing hormone agonist
(s)(GnRH-A) remains the backbone of advanced prostate cancer treatment. In this review …

Measures of substance concentration in urine, serum or other biological matrices often have
an assay limit of detection. When concentration levels fall below the limit, the exact …

Background Orchiectomy has been replaced by medication represented by luteinizing
hormone-releasing hormone (LHRH) agonist as the first-line therapy for androgen …